Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Aurinia Pharmaceuticals director sells over $32k in company stock

Published 05/23/2024, 04:14 AM
AUPH
-

In a recent transaction, Jill Leversage, a director at Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), sold 5,610 shares of the company's common stock for a total value of approximately $32,201 at a price of $5.74 per share.

The sale, which took place on May 21, 2024, was disclosed in a Form 4 filing with the Securities and Exchange Commission. According to the filing's footnote, the shares were sold automatically to cover tax withholding obligations related to the vesting of Restricted Stock Units granted to Leversage on May 19, 2023.

Following the transaction, Leversage still owns 12,918 shares of Aurinia Pharmaceuticals, indicating a continued investment in the company's future. This sale represents a routine financial move often seen among corporate executives, where shares are sold to satisfy tax liabilities incurred from vested equity awards.

Aurinia Pharmaceuticals, which is in the pharmaceutical preparations industry, has its business address in Edmonton, Canada, and is known for its focus on developing therapies for the treatment of serious diseases.

Investors and market watchers often monitor insider transactions such as these for insights into executive sentiment towards their company's stock. While such sales are a normal part of executive compensation and financial planning, they can also provide context to the market on the views of insiders about the company's current valuation and prospects.

InvestingPro Insights

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) has been demonstrating a robust financial posture, with recent InvestingPro Data highlighting a market capitalization of $788.93 million. The company's impressive gross profit margin for the last twelve months as of Q1 2024 stands at 88.82%, reflecting efficient operations and a strong pricing strategy. Despite not being profitable over the last twelve months, Aurinia's net income is expected to grow this year, which is a positive indicator for potential investors.

One of the key InvestingPro Tips for Aurinia Pharmaceuticals is that the management has been actively engaged in share buybacks, which can signal confidence in the company's future and often provides support to the stock price. Additionally, the company holds more cash than debt on its balance sheet, providing it with a solid foundation for future growth or to weather economic downturns.

For those interested in further insights, there are additional InvestingPro Tips available for Aurinia Pharmaceuticals, including analysts' predictions that the company will turn profitable this year. These tips can be a valuable resource for investors looking to make informed decisions. To access these tips and more detailed analytics, consider using InvestingPro, and take advantage of an additional 10% off a yearly or biyearly Pro and Pro+ subscription with the coupon code PRONEWS24.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.